YD Bio Limited (YDES)
NASDAQ: YDES · Real-Time Price · USD
8.01
-0.14 (-1.72%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Company Description
YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs.
The company is based in Taipei, Taiwan.
Contact Details
Address: No. 3, Xingnan St., 12F. Taipei, 115001 Taiwan | |
| Website | ydesgroup.com |
Stock Details
| Ticker Symbol | YDES |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002011674 |
| CUSIP Number | G98301107 |
| ISIN Number | KYG983011076 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ethan Shen Ph.D. | Chief Executive Officer and Chairman |
| Edmund Hen CPA, F.C.A., M.S. | Chief Financial Officer |
| Dr. Benjamin Zhang M.D. | Chief Medical Officer and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 27, 2026 | 424B3 | Prospectus |
| Feb 26, 2026 | 6-K | Report of foreign issuer |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 5, 2026 | 424B3 | Prospectus |
| Jan 30, 2026 | 6-K | Report of foreign issuer |
| Jan 21, 2026 | 6-K | Report of foreign issuer |
| Jan 16, 2026 | 6-K | Report of foreign issuer |
| Jan 15, 2026 | 6-K | Report of foreign issuer |
| Jan 6, 2026 | 6-K | Report of foreign issuer |
| Jan 2, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |